Engineered bacteria churn out cancer biomarkers

September 17, 2020

ITHACA, N.Y. - Pity the glycan.

These complex sugar molecules are attached to 80% of the proteins in the human body, making them an essential ingredient of life. But this process, known as glycosylation, has been somewhat overshadowed by flashier biomolecular processes such as transcription and translation.

"Glycosylation is absolutely essential for life on this planet. And yet, we still know relatively little about it," said Matthew DeLisa, the William L. Lewis Professor of Engineering in the Smith School of Chemical and Biomolecular Engineering. "While much attention has been given to understanding the genome and the proteome, the glycome - which represents the entire complement of sugars, either free or present in more complex molecules such as glycoproteins, of an organism - has been relatively understudied. We need new tools to advance the field forward."

DeLisa's lab has created these very tools by commandeering simple, single-celled microorganisms - namely E. coli bacteria - and engineering them to explore the complex process of glycosylation and the functional role that protein-linked glycans play in health and disease.

The group's paper, "Engineering Orthogonal Human O-linked Glycoprotein Biosynthesis in Bacteria," published July 27 in Nature Chemical Biology. The lead author is Aravind Natarajan, Ph.D. '19.

Previously, DeLisa's team used a similar cell glyco-engineering approach to produce one of the most common types of glycoproteins - those with glycan structures linked to the amino acid asparagine, or N-linked. Now the researchers have turned their attention to another abundant glycoprotein, namely O-linked, in which glycans are attached to the oxygen atom of serine or threonine amino acids of a protein.

The O-linked glycans are more structurally diverse than their N-linked cousins, and they have important implications in the development of new therapeutic treatments for diseases such as breast cancer.

"Our cell-engineering efforts were quite complicated as we not only needed to equip E. coli with the complete set of enzymes for making and attaching glycan structures to proteins, but we also had to carefully rewire native metabolic networks to ensure the availability of important glycan building blocks such as sialic acid," Natarajan said. "The addition of sialic acid to our glycoproteins is significant because this sugar residue is often crucial for targeting drugs to specific cells and increasing their circulatory half-life."

When a cell turns cancerous, it expresses certain biomarkers, including abnormally glycosylated surface proteins, that indicate the presence of cancer. DeLisa's group equipped E. coli with the machinery to produce such proteins, including one that closely resembled a prominent cancer biomarker, mucin 1 (MUC1).

"The glycosylated version of MUC1 is one of the highest-priority target antigens for cancer therapy. It's been very challenging to develop therapies against this target," said DeLisa, the paper's senior author. "But by having a biosynthetic tool like the one we've created that is capable of replicating the MUC1 structure, we're hopeful that this could provide glycoprotein reagents that could be leveraged to discover antibodies or employed directly as immunotherapies, all of which could help in the fight against certain types of cancer."

Both O-linked and N-linked glycans have also been discovered in one of the surface proteins of the SARS-CoV-2 virus, which causes COVID-19. DeLisa is hopeful his group's method of bacterial cell glyco-engineering will open the door for creating glycosylated versions of this S-protein that could lead to therapeutic antibodies against the coronavirus, or the development of a subunit vaccine.

Because of their earlier work replicating N-linked glycans, the researchers were able to get the O-linked system up and running quickly. Now DeLisa's lab is primed to make proteins that carry both types of glycosylation, which is significant because many glycoproteins, such as the S-protein in SARS-CoV-2, carry both N- and O-linked glycan structures.

The researchers are also exploring ways to increase the spectrum of glycoproteins that their engineered E. coli cells can produce and the efficiency with which these products are generated.

"We think of E. coli as a clean chassis or a blank slate when it comes to protein glycosylation, because these bacteria do not normally peform glycosylation reactions like the ones we have installed," DeLisa said. "This allows construction of these pathways from the bottom up, giving us total control over the types of glycan structures that are made, and the specific sites in target proteins where they're attached. That is a level of control that is difficult to achieve with other preexisting cell-based systems or technologies for glycoprotein engineering."
-end-
Contributing authors include: Jeffrey Varner, professor in the Smith School of Chemical and Biomolecular Engineering; undergraduate researchers Marielisa Cabrera-Sánchez '18, Jody Mohammed '20 and Olivia Young '19; Emily Cox, Ph.D. '19; Michael Vilkhovoy, Ph.D. '19; doctoral students Thapakorn Jaroentomeechai and Sandra Vadhin; and researchers from the University of Georgia's Complex Carbohydrate Research Center.

The research was supported by the Defense Threat Reduction Agency, the National Science Foundation, the National Institutes of Health and the Cornell Center on the Physics of Cancer Metabolism. The researchers made use of the Cornell Institute of Biotechnology, where DeLisa serves as director.

Cornell University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.